Tezacitabine
Alternative Names: FMdc; KW 2331; MDL 101731Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Aventis
- Class Antineoplastics; Nucleosides; Small molecules
- Mechanism of Action Ribonucleoside triphosphate reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Colorectal cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Viral infections
Most Recent Events
- 22 Mar 2004 Discontinued - Phase-I for Solid tumours in Japan (IV)
- 22 Mar 2004 Discontinued - Phase-I for Solid tumours in USA (IV)
- 22 Mar 2004 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)